Browsing by Author "Toklu T."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Acceptance Tests and Quality Control of the Positron Emission Tomography (PET) Systems; [Pozitron Emisyon Tomografi (PET) sistemlerinin kalite kontrolü ve kabul Testleri]
    (Galenos Publishing House, 2020) Hacıosmanoğlu T.; Demir M.; Toklu T.; Suna Kıraç F.; İnce M.; Parlak Y.; Kovan B.; Dönmez S.; Ayan A.; Özaslan İ.A.; Hiçürkmez M.; Yeyin N.; Poyraz L.
    Quality control (QC) applications are important for the reliability and accuracy of the results obtained from positron emission tomography (PET) imaging systems in clinical trials. With these applications, exposure of patients and employees to more radiation will be prevented, and it will be possible to detect the systems that lost their performance compared to their installation time. QC applications are grouped as acceptance and reference tests, routine periodic QC tests. PET performance tests standardized by National Electrical Manufacturers Association (NEMA) should be used as acceptance and reference tests. In addition, the performance of the device should be monitored by following these tests at six-month intervals. PET/computerized tomography (CT) manufacturers often recommend routine QC procedures for their equipment and require users to follow these recommendations to a minimum. If standards are not defined for routine QC procedures, it is recommended to comply with the general minimum standards for routine QC that all PET/CT centers must perform. Routine QC protocols, the image quality of the PET system; CT image quality and CT dose of the patient; the accuracy of CT-based attenuation corrections; the accuracy of the CT and PET co-registration should ensure that problems that can interact any of the performance characteristics are identified. Since performing PET/CT scans by equipment that does not comply with their specifications may compromise image quality, interpretation of images and reliability of results, daily QC parameters must be evaluated and necessary corrective procedures must be taken prior to scanning. The tests are carried out using the protocol provided by the manufacturer. © Telif Hakkı 2020 Türkiye Nükleer Tıp Derneği / Nükleer Tıp Seminerleri, Galenos Yayınevi tarafından yayınlanmıştır.
  • No Thumbnail Available
    Item
    Acceptance and Quality Control Tests for the Single Photon Emission Computerized Tomography (SPECT) Gamma Cameras and SPECT/CT Systems; [Tek Foton Emisyon Kompüterize Tomografi (SPECT) Gama Kameralar ve SPECT/BT Sistemleri için Kabul ve Kalite Kontrol Testleri]
    (Galenos Publishing House, 2020) Dönmez S.; Ayan A.; Parlak Y.; Kovan B.; Hiçürkmez M.; Kıraç F.S.; Demir M.; Toklu T.; Hacıosmanoğlu T.; Özaslan İ.A.; Poyraz L.; ve Kalite Kontrol Çalışma Grubu Üyeleri T.R.G.
    Scintigraphic images play an important role in the diagnosis of diseases by providing accurate clinical information independent of the operator. However, the good quality image may not be obtained due to changes in the performance of the imaging system and/or external factors. A poor quality image will make difficult to interpretate clinical studies. Quality Control (QC) tests provide to reveal the conditions that will adversely affect the image quality before starting of scintigraphic imaging, and to make the necessary arrangements. Although QC tests show relative changes depending on the brand and model of gama camera, there are tests that must be done routinely. For gamma cameras [planar and single photon emission computerized tomography (SPECT)] to be newly installed in the Nuclear Medicine Clinic, “Acceptance Tests” should be carried out after the installation. “Checks before clinical studies” before. © Telif Hakkı 2020 Türkiye Nükleer Tıp Derneği / Nükleer Tıp Seminerleri, Galenos Yayınevi tarafından yayınlanmıştır.
  • No Thumbnail Available
    Item
    The radiolabeling of [161Tb]Tb-PSMA-617 by a novel radiolabeling method and preclinical evaluation by in vitro/in vivo methods
    (Akademiai Kiado ZRt., 2024) Uygur E.; Sezgin C.; Parlak Y.; Karatay K.B.; Arıkbaşı B.; Avcıbaşı U.; Toklu T.; Barutça S.; Harmanşah C.; Sözen T.S.; Maus S.; Scher H.; Aras O.; Gümüşer F.G.; Biber Muftuler F.Z.
    Prostate cancer (PC) is the most prevalent cancer in elderly men, exhibiting a positive correlation with age. As resistance to treatment has developed, particularly in the progressive stage of the disease and in the presence of microfocal multiple bone metastases, new generation radionuclide therapies have emerged. Recently introduced for treating micrometastatic foci, Terbium-161 ([161Tb]) has shown great promise in prostate cancer treatment. This study investigated the in vitro and in vivo cytotoxicity of Terbium-161 ([161Tb])-radiolabeled prostate-specific membrane antigen (PSMA)-617. [161Tb]Tb-PSMA-617 (7.4 MBq/nmol) demonstrated a radiochemical yield of 97.99 ± 2.01% and hydrophilicity. [161Tb]Tb-PSMA-617 was also shown to have good stability, with a radiochemical yield of over 95% up to 72 h. In vitro, [161Tb]Tb-PSMA-617 exhibited cytotoxicity on LNCaP cells but not on PC3 cells. In vivo, scintigraphy imaging visualized the accumulation of [161Tb]Tb-PSMA-617 in the prostate, kidneys, and bladder. The results suggest that [161Tb]Tb-PSMA-617 can be an effective radiolabeled agent for the treatment of PSMA positive foci in prostate cancer. © Akadémiai Kiadó, Budapest, Hungary 2024.